136 related articles for article (PubMed ID: 32024681)
1. Epigenetic Modulation of the Tumor Immune Microenvironment to Potentiate Immune Checkpoint Blockade Therapy.
Menzel J; Black JC
Cancer Discov; 2020 Feb; 10(2):179-181. PubMed ID: 32024681
[TBL] [Abstract][Full Text] [Related]
2.
Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
[TBL] [Abstract][Full Text] [Related]
3. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
4. Systematic
Walter DM; Venancio OS; Buza EL; Tobias JW; Deshpande C; Gudiel AA; Kim-Kiselak C; Cicchini M; Yates TJ; Feldser DM
Cancer Res; 2017 Apr; 77(7):1719-1729. PubMed ID: 28202515
[TBL] [Abstract][Full Text] [Related]
5. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
6.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
7. In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis.
Wu Q; Tian Y; Zhang J; Tong X; Huang H; Li S; Zhao H; Tang Y; Yuan C; Wang K; Fang Z; Gao L; Hu X; Li F; Qin Z; Yao S; Chen T; Chen H; Zhang G; Liu W; Sun Y; Chen L; Wong KK; Ge K; Chen L; Ji H
Proc Natl Acad Sci U S A; 2018 Apr; 115(17):E3978-E3986. PubMed ID: 29632194
[TBL] [Abstract][Full Text] [Related]
8. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
[No Abstract] [Full Text] [Related]
9. Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy.
Li Y; Yang C; Liu Z; Du S; Can S; Zhang H; Zhang L; Huang X; Xiao Z; Li X; Fang J; Qin W; Sun C; Wang C; Chen J; Chen H
Mol Cancer; 2022 Jan; 21(1):2. PubMed ID: 34980132
[TBL] [Abstract][Full Text] [Related]
10. Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers.
Della Corte CM; Byers LA
Cancer Discov; 2019 Jan; 9(1):16-18. PubMed ID: 30626603
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Wang G; Chow RD; Zhu L; Bai Z; Ye L; Zhang F; Renauer PA; Dong MB; Dai X; Zhang X; Du Y; Cheng Y; Niu L; Chu Z; Kim K; Liao C; Clark P; Errami Y; Chen S
Cancer Discov; 2020 Dec; 10(12):1912-1933. PubMed ID: 32887696
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy.
Kawakubo K; Castillo CF; Liss AS
J Gastroenterol; 2022 Nov; 57(11):819-826. PubMed ID: 36048239
[TBL] [Abstract][Full Text] [Related]
13. Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.
Falk AT; Yazbeck N; Guibert N; Chamorey E; Paquet A; Ribeyre L; Bence C; Zahaf K; Leroy S; Marquette CH; Cohen C; Mograbi B; Mazières J; Hofman V; Brest P; Hofman P; Ilié M
Lung Cancer; 2018 Jul; 121():70-75. PubMed ID: 29858030
[TBL] [Abstract][Full Text] [Related]
14. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
[TBL] [Abstract][Full Text] [Related]
15. Turning Up the Heat on the Pancreatic Tumor Microenvironment by Epigenetic Priming.
Nephew KP
Cancer Res; 2020 Nov; 80(21):4610-4611. PubMed ID: 33144295
[TBL] [Abstract][Full Text] [Related]
16. Mutant KRAS at the Heart of Tumor Immune Evasion.
van Maldegem F; Downward J
Immunity; 2020 Jan; 52(1):14-16. PubMed ID: 31951548
[TBL] [Abstract][Full Text] [Related]
17. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
Kitajima S; Ivanova E; Guo S; Yoshida R; Campisi M; Sundararaman SK; Tange S; Mitsuishi Y; Thai TC; Masuda S; Piel BP; Sholl LM; Kirschmeier PT; Paweletz CP; Watanabe H; Yajima M; Barbie DA
Cancer Discov; 2019 Jan; 9(1):34-45. PubMed ID: 30297358
[No Abstract] [Full Text] [Related]
18. In vivo multidimensional CRISPR screens identify
Ji P; Gong Y; Jin ML; Wu HL; Guo LW; Pei YC; Chai WJ; Jiang YZ; Liu Y; Ma XY; Di GH; Hu X; Shao ZM
Sci Adv; 2022 Jul; 8(26):eabl8247. PubMed ID: 35767614
[TBL] [Abstract][Full Text] [Related]
19. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.
Molina-Arcas M; Downward J
Cancer Cell; 2024 Mar; 42(3):338-357. PubMed ID: 38471457
[TBL] [Abstract][Full Text] [Related]
20. Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy.
Etxeberria I; Teijeira A; Montuenga LM; Berraondo P; Melero I
Cancer Discov; 2018 Jul; 8(7):794-796. PubMed ID: 29967073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
